Log in
Enquire now
Eligo Bioscience

Eligo Bioscience

Eligo Bioscience is a developer of novel genetic medicines founded in 2014 by Timothy Lu, Xavier Duportet, Luciano Marraffini and David Bikard.

OverviewStructured DataIssuesContributors

Contents

eligo.bio
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Probiotics
Probiotics
Therapeutics
Therapeutics
0
Drug discovery
Drug discovery
Drug development
Drug development
Microbiome
Microbiome
...
Location
Paris
Paris
France
France
Boston, New York
Boston, New York
B2X
B2B
B2B
CEO
‌
Xavier Duportet
Founder
Timothy Lu
Timothy Lu
‌
Xavier Duportet
David Bikard
David Bikard
‌
Luciano Marraffini
AngelList URL
angel.co/company/el...-bioscience
Pitchbook URL
pitchbook.com/profiles...108026-92
Date Incorporated
2014
Spun Out From
Massachusetts Institute of Technology
Massachusetts Institute of Technology
Number of Employees (Ranges)
11 – 50
Email Address
contact@eligo-bioscience.com
Full Address
29 rue du Faubourg Saint-Jacques 75014 Paris France
Investors
Sanofi Ventures
Sanofi Ventures
Agoranov
Agoranov
EASME (EU Executive Agency for SMEs)
EASME (EU Executive Agency for SMEs)
Khosla Ventures
Khosla Ventures
Bpifrance
Bpifrance
Seventure Partners
Seventure Partners
‌
France 2030
Founded Date
2014
Total Funding Amount (USD)
87,563,140
Latest Funding Round Date
May 14, 2025
Board of Directors
‌
Aurélie Grienenberger
‌
Sébastien Groyer
David Bikard
David Bikard
‌
Edith Hessel
‌
Xavier Duportet
‌
Jean-Pierre Lehner
Samir Kaul
Samir Kaul
CTO
David Bikard
David Bikard
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
3
Wellfound ID
eligo-bioscience
Technologies Used
CRISPR
CRISPR
Country
France
France
Headquarters
Paris
Paris

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
5,000,000

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.

Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”.

Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.

Funding
Seed

On July 9, 2015 Eligo Bioscience completed their seed funding round with €2.6M from Seventure Partners (lead investor) and Worldwide Innovation Challenge.

Series A

On September 26, 2017 Eligo Bioscience completed their series A funding round with $20million in funding from Seventure Partners and Khosla Ventures.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Eligo Bioscience

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.